Warda Niaz
Endocrinology, Diabetes & Metabolism · Montgomery, ALNPI 1184090656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 452 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,412 and has fallen 97.1% since, to $70 in 2025.
Across 452 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Dexcom, Inc.$973
- Novo Nordisk$863
- Sanofi-aventis U.S. LLC$515
- Mannkind Corporation$490
- Antares Pharma, Inc.$328
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,916100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 78 | $1,306 |
| Dexcom, Inc. | 92 | $973 |
| Novo Nordisk | 42 | $863 |
| Sanofi-aventis U.S. LLC | 27 | $515 |
| Mannkind Corporation | 14 | $490 |
| Antares Pharma, Inc. | 14 | $328 |
| AstraZeneca(2 entities) | 19 | $321 |
| Boehringer Ingelheim | 19 | $300 |
| Corcept Therapeutics | 17 | $294 |
| Amgen(2 entities) | 17 | $283 |
| Xeris Pharmaceuticals, Inc. | 13 | $265 |
| Bayer | 14 | $255 |
| Medtronic(2 entities) | 7 | $223 |
| Amarin Pharma, Inc. | 11 | $221 |
| Abbott | 11 | $187 |
| IBSA Pharma Inc. | 8 | $149 |
| Radius Health, Inc. | 6 | $142 |
| BETA Bionics, Inc. | 6 | $134 |
| AbbVie | 6 | $112 |
| Amryt Pharma Holdings Ltd | 5 | $104 |
| Novartis | 5 | $97 |
| Insulet Corporation | 4 | $71 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| Tandem Diabetes Care, Inc. | 2 | $39 |
| Recordati_rare_diseases_inc. | 2 | $30 |
| Pfizer | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Vivus LLC | 1 | $15 |
How this compares
$7,928 in reported general payments places this provider in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 733 | $850,658 |
| OzempicSemaglutide | 456 | $517,696 |
| JardianceEmpagliflozin | 236 | $235,290 |
| FarxigaDapagliflozin Propanediol | 108 | $95,982 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $94,253 |
| RybelsusSemaglutide | 63 | $83,260 |
| Tresiba Flextouch U-100Insulin Degludec | 96 | $69,838 |
| Humulin R U-500Insulin Regular, Human | 24 | $61,044 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 55 | $52,552 |
| TrulicityDulaglutide | 39 | $51,926 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $39,930 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 36 | $38,369 |
| Repatha SureclickEvolocumab | 60 | $36,277 |
| GenotropinSomatropin | 13 | $33,439 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $30,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,306 | $927,556846 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $863 | $616,733566 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $300 | $296,635307 claims |
| AstraZenecaFarxiga | $321 | $95,982108 claims |
| PfizerGenotropin | $30 | $33,43913 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $515 | $23,71931 claims |
| AbbVieSynthroid | $112 | $13,430149 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $13,333537 claims |
| Antares Pharma, Inc.Xyosted | $328 | $12,28912 claims |
| IBSA Pharma Inc.Tirosint | $149 | $5,38826 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $24 | $3,45511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Montgomery
- Hima AmmanaMontgomery$9K
- Manisha GargMontgomery$8K
- Vaishall ThudiMontgomery$8K
- Elaina AdderleyMontgomery$7K
- Ahsan FarooqMontgomery$4K
- Mohammad-Ehsan OwrangiMontgomery$3K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.